Literature DB >> 7760060

Comparison of (R)-[3H]tomoxetine and (R/S)-[3H]nisoxetine binding in rat brain.

D R Gehlert1, D A Schober, S L Gackenheimer.   

Abstract

(R)-[3H]Tomoxetine is a radioligand that binds to the norepinephrine (NE) uptake site with high affinity but also binds to a second, lower-affinity site. The goal of the present study was to identify the nature of this low-affinity site by comparing the binding properties of (R)-[3H]tomoxetine with those of (R/S)-[3H]nisoxetine, a highly selective ligand for the NE uptake site. In homogenate binding studies, both radioligands bound to the NE uptake site with high affinity, whereas (R)-[3H]tomoxetine also bound to a second, lower-affinity site. The autoradiographic distribution of binding sites for both radioligands is consistent with the known distribution of NE-containing neurons. However, low levels of (R)-[3H]tomoxetine binding were seen in the caudate-putamen, globus pallidus, olfactory tubercle, and zona reticulata of the substantia nigra, where (R/S)-[3H]nisoxetine binding was almost absent. In homogenates of the caudate-putamen, the NE uptake inhibitors desipramine and (R)-nisoxetine and the serotonin (5-HT) uptake inhibitor citalopram produced biphasic displacement curves. Autoradiographic studies using 10 nM (R)-nisoxetine to mask the binding of (R)-[3H]tomoxetine to the NE uptake site produced autoradiograms that were similar to those produced by [3H]citalopram. Therefore, (R)-[3H]tomoxetine binds to the NE uptake site with high affinity and the 5-HT uptake site with somewhat lower affinity.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7760060     DOI: 10.1046/j.1471-4159.1995.64062792.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  15 in total

1.  Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes.

Authors:  M Mantovani; D J Dooley; A Weyerbrock; R Jackisch; T J Feuerstein
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

2.  X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine.

Authors:  Aravind Penmatsa; Kevin H Wang; Eric Gouaux
Journal:  Nat Struct Mol Biol       Date:  2015-05-11       Impact factor: 15.369

3.  Mesolimbic dopamine super-sensitivity in melanin-concentrating hormone-1 receptor-deficient mice.

Authors:  Daniel G Smith; Eleni T Tzavara; Janice Shaw; Susan Luecke; Mark Wade; Richard Davis; Craig Salhoff; George G Nomikos; Donald R Gehlert
Journal:  J Neurosci       Date:  2005-01-26       Impact factor: 6.167

Review 4.  Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.

Authors:  Dene Simpson; Greg L Plosker
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 5.  Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Authors:  Karly P Garnock-Jones; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

6.  Profile of sexual and genitourinary treatment-emergent adverse events associated with atomoxetine treatment: a pooled analysis.

Authors:  Angelo Camporeale; Kathleen Ann Day; Dustin Ruff; Jody Arsenault; David Williams; Douglas K Kelsey
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

7.  Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram.

Authors:  Jean D Deupree; Megan D Montgomery; David B Bylund
Journal:  Eur J Pharmacol       Date:  2007-08-23       Impact factor: 4.432

Review 8.  Atomoxetine.

Authors:  Dene Simpson; Caroline M Perry
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Differential effects of neonatal norepinephrine lesions on immediate early gene expression in developing and adult rat brain.

Authors:  J D Sanders; H K Happe; D B Bylund; L C Murrin
Journal:  Neuroscience       Date:  2008-10-01       Impact factor: 3.590

Review 10.  Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.

Authors:  Dene Simpson; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.